Sanofi (SNY) Releases Q4 2025 Earnings: Revenue Up but Operating and Net Losses

Sanofi (SNY) delivered strong revenue growth in fourth-quarter 2025 but reported operating and net losses for the period.

Total revenue: $14.3 billion (+20.5% year-over-year).

Gross profit: $9.9 billion (+21.45% year-over-year).

Operating result: -$1.2 billion (change -223.85% year-over-year).

Net income attributable to shareholders: -$940 million (change -280.99% year-over-year).

Diluted earnings per share: -$0.39 per share (change -285.71% year-over-year).

On the cash-flow and balance-sheet side, the company showed positive operating cash generation and a solid cash position despite higher investment.

Cash from operating activities: $4.0 billion (+12.83% year-over-year).

Purchases of property, plant and equipment: -$837 million (+20.58% year-over-year).

Cash and cash equivalents: $9.0 billion (+16.03% year-over-year).

Cost of sales: $4.4 billion (+18.43% year-over-year).

Total liabilities: $64.6 billion (+13.07% year-over-year).

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Sanofi Hedge Fund Activity

We have seen 319 institutional investors add shares of Sanofi stock to their portfolio, and 345 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL WORLD INVESTORS removed 8,354,084 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $394,312,764
INVESCO LTD. removed 3,390,657 shares (-36.9%) from their portfolio in Q3 2025, for an estimated $160,039,010
DODGE & COX removed 2,786,568 shares (-3.9%) from their portfolio in Q3 2025, for an estimated $131,526,009
RAYMOND JAMES FINANCIAL INC removed 2,443,717 shares (-41.6%) from their portfolio in Q3 2025, for an estimated $115,343,442
THRIVENT FINANCIAL FOR LUTHERANS added 2,079,366 shares (+1722.2%) to their portfolio in Q3 2025, for an estimated $98,146,075
MILLENNIUM MANAGEMENT LLC added 1,319,379 shares (+1151.8%) to their portfolio in Q3 2025, for an estimated $62,274,688
BNP PARIBAS FINANCIAL MARKETS added 859,246 shares (+422.1%) to their portfolio in Q3 2025, for an estimated $40,556,411

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Sanofi Government Contracts

We have seen $72,824,829 of award payments to $SNY over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

MAINTAINING OF EMBRYONATED EGG SUPPLY FOR NON-SEASONAL PRODUCTION OF PANDEMIC VACCINE: $26,599,493
TO CONDUCT A CLINICAL TRIAL TO ASSESS THE SAFETY, IMMUNOGENICITY, ANTIGEN DOSE, OF MATRIX-M ADJUVANT IN COM...: $24,873,330
8511229112!INFLUENZA VIRUS VAC: $6,025,705
THE PURPOSE OF THIS REQUIREMENT IS TO PROVIDE MEDICAL COUNTERMEASURES (MCMS), SUCH AS VACCINES AND ADJUVANT...: $3,906,468
8511228595!INFLUENZA VIRUS VAC: $3,893,798

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

Sanofi Congressional Stock Trading

Members of Congress have traded $SNY stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $SNY stock by members of Congress over the last 6 months:

REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 08/04 and 1 sale worth up to $15,000 on 09/11.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

Sanofi Analyst Ratings

Wall Street analysts have issued reports on $SNY in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Jefferies issued a "Buy" rating on 10/27/2025
Morgan Stanley issued a "Overweight" rating on 09/08/2025
Deutsche Bank issued a "Buy" rating on 09/02/2025

To track analyst ratings and price targets for Sanofi, check out Quiver Quantitative's $SNY forecast page.